SWOG S1222: Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor Positive Stage IV Breast Cancer
This study is for women who are postmenopausal and have breast cancer that has spread to other parts of the body (metastasized).
The purpose of this study is to find out what effects, by adding the drugs anastrozole and everolimus to regular treatment with fulvestrant has on metastatic breast cancer. Anastrozole, everolimus and fulvestrant are all approved by the Food and Drug Administration for the treatment of metastatic breast cancer. It is the combination of the three drugs that is considered investigational.
Patients will be followed for approximately 5 years.